Cambridge, MA, October 28, 2024 –Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announces the appointment of Carol Satler, M.D., PhD, as Vice President for Non-oncology programs Clinical Development. Based in Boston, U.S., Dr. Satler will report directly to Sujata Rao, M.D., Chief Medical Officer of Insilico Medicine. In her new role, Dr. Satler will play a pivotal role in the further clinical validation of Insilico’s leading program ISM001-055 — the first-in-class treatment for idiopathic pulmonary fibrosis developed with the support of Insilico’s Pharma.AI platform. Additionally, she will be responsible for high-level strategic planning and clinical study protocol design for Insilico's diversified AI-driven portfolio, overseeing the preparation and execution of clinical validation for the company's non-oncology assets.